Paper · 42941789
pH-Responsive Erdafitinib Liposomes with FGFR3 Targeting for Intravesical Bladder Cancer Therapy.
Liang H and 8 others. Int J Mol Sci, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. pH-Responsive Erdafitinib Liposomes with FGFR3 Targeting for Intravesical Bladder Cancer Therapy. Papers, record 42941789. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42941789
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- pH-Responsive Erdafitinib Liposomes with FGFR3 Targeting for Intravesical Bladder Cancer Therapy.
- Journal
- Int J Mol Sci
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-28
Source PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptor, Fibroblast Growth Factor, Type 3 | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Liposomes | Major topic |
| Pyrazoles | Major topic |
| Quinoxalines | Major topic |
| Antineoplastic Agents | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Cell Line, Tumor | |
| Hydrogen-Ion Concentration | |
| Mice, Nude | |
| Mice, Inbred BALB C | |
| Xenograft Model Antitumor Assays | |
| Administration, Intravesical | |
| Female | |
| Cell Proliferation |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82372035 | National Natural Science Foundation of China | PubMed | ||
| 82572373 | National Natural Science Foundation of China | PubMed | ||
| 2025SF-YBXM-392 | Key Research and Development Program of Shaanxi Province | PubMed | ||
| 2024RCYGXXP | Sword Action Talent Program | PubMed | ||
| LHJJ24YG06 | Joint Funding Project of Innovation Research Institute of Xijing Hospital | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References58
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41,483,136 | Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysis. | Int Urol Nephrol | 2026 | https://conductscience.org/library/papers/41483136 | PubMed |
| 2 | 41,539,604 | Comment on: ALBAN (GETUG-AFU 37): a phase III, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). | Ann Oncol | 2026 | https://conductscience.org/library/papers/41539604 | PubMed |
| 3 | 40,521,274 | Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer. | Eur Urol Open Sci | 2025 | https://conductscience.org/library/papers/40521274 | PubMed |
| 4 | 39,161,208 | FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies. | Cancer Commun (Lond) | 2024 | https://conductscience.org/library/papers/39161208 | PubMed |
| 5 | 40,330,044 | Progress on liposome delivery systems in the treatment of bladder cancer. | RSC Adv | 2025 | https://conductscience.org/library/papers/40330044 | PubMed |
| 6 | 39,353,825 | FGFR Inhibition in Urothelial Carcinoma. | Eur Urol | 2025 | https://conductscience.org/library/papers/39353825 | PubMed |
| 7 | 39,664,414 | Strategies for intravesical drug delivery: From bladder physiological barriers and potential transport mechanisms. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/39664414 | PubMed |
| 8 | 39,342,596 | Intravesical Gemcitabine for Non-Muscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure: A Prospective Study. | Asian Pac J Cancer Prev | 2024 | https://conductscience.org/library/papers/39342596 | PubMed |
| 9 | 38,732,167 | Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38732167 | PubMed |
| 10 | 30,397,178 | Long Noncoding RNA LBCS Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30397178 | PubMed |
1 to 10 of 58
See all 58 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42941789
GET https://conductscience.org/api/papers/v1/42941789/references?page=2